Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges (2010 - 2026)

Jazz Pharmaceuticals' Amortization of Deferred Charges history runs 16 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 72.51% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $20.1 million, a 39.12% decrease from a year earlier, with the FY2025 full-year figure at $32.5 million, up 48.1% from the prior year.
• Amortization of Deferred Charges declined to $4.7 million in Q1 2026 per JAZZ's latest filing, from $5.3 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $17.1 million in Q1 2025 and bottomed at $3.1 million in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $5.6 million (2022), against an average of $7.0 million.
• Across the five-year window, Amortization of Deferred Charges tumbled 77.55% in 2022 and jumped 185.57% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $6.0 million in 2022, then climbed by 2.55% to $6.1 million in 2023, then sank by 49.44% to $3.1 million in 2024, then surged by 72.13% to $5.3 million in 2025, then dropped by 11.8% to $4.7 million in 2026.
• Per Business Quant, the three latest JAZZ Amortization of Deferred Charges figures stand at $4.7 million (Q1 2026), $5.3 million (Q4 2025), and $5.3 million (Q3 2025).